107
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Years of potential life lost due to HIV infection and associated factors based on national HIV surveillance data in Latvia, 1991–2010

, &
Pages 140-146 | Received 17 May 2012, Accepted 30 Jul 2012, Published online: 19 Sep 2012

References

  • European Communities, Eurostat. Health statistics—atlas on mortality in the European Union 2009. Luxembourg: Office for Official Publications of the European Communities; 2009 pp. 7–63.
  • Gardner JW, Sanborn JS. Years of potential life lost (YPLL)—what does it measure? Epidemiology 1990;1:322–9.
  • McDonnell S, Vossberg K, Hopkins RS, Mittan B. Using YPLL in health planning. Public Health Rep 1998;113: 55–61.
  • Selik RM, Chu SY. Years of potential life lost due to HIV infection in the United States. AIDS 1997;11:1635–93.
  • Šemerl JŠ, Šešok J. Years of potential life lost and valued years of potential life lost in assessing premature mortality in Slovenia. Croat Med J 2002;43:439–45.
  • McDavid Harrison K, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010;53:124–30.
  • Lai D, Hardy RJ. Potential gains in life expectancy or years of potential life lost: impact of competing risks of death. Int J Epidemiol 1999;28:894–8.
  • Rozentāle G, Skrule J, Štāle M, Zvaigznīte I. [Years of potential life lost in Latvia in 2010] (in Latvian). Riga: National Health Service; 2011 pp. 6–13.
  • DesMeules M, Manuel D, Cho R. Mortality: life and health expectancy of Canadian women. BMC Womens Health 2004;4:S9.
  • European Centre for Disease Prevention and Control; WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2010. Stockholm: ECDC; 2011 pp. 21–49.
  • Eurostat Search Database (database online). March 21, 2012 update. Eurostat: European Commission; 2012.
  • European Centre for Disease Prevention and Control. Country mission report. Latvia country visit HIV, STI and hepatitis B and C. Stockholm: ECDC; 2011 pp. 4–13.
  • Aragon TJ, Lichtensztajn DY, Katcher BS, Reiter R, Katz MH. Calculating expected years of life lost for assessing local ethnic disparities in causes of premature death. BMC Public Health 2008;8:116.
  • Drūtyte G, Gurevičius R. Years and valued years of potential life lost due to external causes of death in Lithuania, 2000–2006. Presented at the 5th International Vilnius Conference, EURO Mini Conference KORSD 2009.
  • The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293–9.
  • Ivey MA, Legall G, Boisson EV, Hinds A. Mortality trends and potential years of life lost in the English and Dutch-speaking Caribbean, 1985–2000. West Indian Med J 2008; 57:122–31.
  • Schanzer DL. Trends in HIV/AIDS Mortality in Canada, 1987–1998. Can J Public Health 2003;94:135–9.
  • Conti S, Masocco M, Farchi G, Rezza G, Toccaceli V. Premature mortality in Italy during the first decade of the AIDS epidemic: 1984–1993. Int J Epidemiol 1997;26:873–9.
  • Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer 2005;92:241–5.
  • Mazurek JM, Wood JM. Asbestosis-related years of potential life lost before age 65 years—United States, 1968–2005. MMWR Morb Mortal Wkly Rep2008;57:1321–5.
  • Peters TJ. Multifarious terminology: multivariable or multivariate? Univariable or univariate? Paediatr Perinat Epidemiol 2008;22:506.
  • Mills EJ, Bakanda C, Birungi J, Chan K, Hogg RS, Ford N, . Male gender predicts mortality in large cohort of patients receiving antiretroviral therapy in Uganda. AIDS 2011;14:52.
  • Bermudez-Tamayo C, Martin JJ, Ruiz-Pérez I, Lima AO. Factors associated with improvement in disability-adjusted life years in patients with HIV/AIDS. BMC Public Health 2008;8:362.
  • Laukamm-Josten U, de Colombani P, de Joncheere K, Drew R, Eramova I, Rotberga S, . Mid-term evaluation of the Latvian national HIV programme: 2009–2013. WHO, UNODC; March 2011 pp. 37–39. Available at: http://phoebe.vm.gov.lv/misc_db/web.nsf/626e6035eadbb4cd85256499006b15a6/ab75e1a6c38b637dc22573d800293aaa/$FILE/WHO_UNODC%20mission%20Final%20report_Latvia.pdf (accessed 16 May 2012)
  • Pérez-Hoyos S, del Amo J, Muga R, del Romero J, García de Olalla P, Guerrero R, . Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003;17:353–9.
  • Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, . Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267–74.
  • Lloyd-Smith E, Brodkin E, Wood E, Kerr T, Tyndall MW, Montaner JS, . Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006;20:445–50.
  • Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010;14:731–47.
  • Cargill VA, Stone VE. HIV/AIDS: a minority health issue. Med Clin North Am 2005;89:895–912.
  • Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2010. UNAIDS; 2010.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.